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CORRESPONDENCE
Fluoroquinolones: are they essential to treat multidrug-
resistant tuberculosis?
To the Editors:
We read with interest the excellent letter by HOLTZ and
CEGIELSKI [1] contributing to the current discussion on
extensively drug-resistant (XDR)-tuberculosis (TB). Several
publications have already demonstrated that resistance to
fluoroquinolones (FQ) is independently associated with poor
outcome and/or that the possibility of including FQ in
regimens improves treatment outcomes of multidrug-resistant
(MDR)-TB cases [2–4]. This happened before the (recent)
description of XDR-TB [1, 5]. We do not know how many of
the patients with MDR-TB strains were, in fact, infected with
XDR Mycobacterium tuberculosis.
We wanted to establish the role of the different XDR-defining
components (e.g. isoniazid and rifampicin, FQ and injectable
second-line drugs) in determining poor treatment outcomes.
Our group has shown for the first time that XDR-TB cases in Italy
and Germany have a five-fold increase in the risk of death
(relative risk (RR) 5.45; 95% confidence interval (CI) 1.95–15.27;
p,0.01), require longer hospitalisation than MDR-TB cases
(241.2¡177.0 versus 99.1¡85.9 days; p,0.001), have a longer
treatment duration (30.3¡29.4 versus 15.0¡23.8 months; p,0.05)
and, for the few cases who converted, need a longer time to
smear/culture conversion (p,0.01) [6]. The findings of a second
study, which included additional cases from Estonia and the
Russian Federation, demonstrated that XDR-TB cases had an RR
of 1.58 to achieve death or failure compared with MDR-TB cases
resistant to all first-line drugs (95% CI 1.14–2.20; p,0.05) and an
RR of 2.61 (95% CI 1.45–4.69; p,0.001) compared with MDR-TB
cases in which susceptibility to at least one first-line drug still
existed [7]. These data support the observation that the loss of
first-line drugs different from rifampicin and isoniazid has a role
in worsening prognosis of MDR-TB cases.
In order to better understand the role of FQ in determining
poor treatment outcomes in MDR-TB cases, we re-analysed
data from the four-country study [7] to assess whether there is
any difference in death or mortality in MDR-TB cases resistant
or susceptible to FQ. The overall sample included 425 MDR-TB
cases (361 MDR, 64 XDR). A total of 87 (20%) were resistant to
FQ, 23 (26%) being MDR and 64 (74%) XDR. Although the
proportion of MDR-TB cases resistant to FQ was similar in the
three countries reporting FQ resistance (i.e. 18, 24 and 24% in
Italy, Germany and Estonia, respectively), the proportion of
XDR-TB cases among FQ-resistant cases was largely different
(50, 27 and 88% in Italy, Germany and Estonia, respectively).
FQ-resistant MDR-TB cases yielded a higher proportion of
deaths than non-FQ-resistant cases (20 versus 12%; p50.020), as
well as a higher proportion of treatment failures (19 versus 9%;
p50.038; table 1).
At the multiple regression analysis, the presence of XDR-TB is
the only independent risk factor for both death (odds ratio
(OR) 2.07; 95% CI 1.05–4.05; p,0.034) and failure (OR 2.37; 95%
CI 1.14–4.89; p,0.02). The findings of our analysis suggest that
FQ contribute to increase the risk of death and failure, being a
key XDR-defining variable.
In conclusion, apart from linezolid, fluoroquinolones represent
the only ‘‘new’’ class of active drugs currently available to treat
drug-resistant tuberculosis. They are effective and relatively well
tolerated. Furthermore, fluoroquinolones have the potential to
allow a reduction in the (still long) short-course chemotherapy
regimens. Unfortunately, rapid selection of drug resistance
mutants to fluoroquinolones is a well-known phenomenon.
Prevention of development of further drug resistance is impera-
tive until new drugs become available in the treatment arena.
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TABLE 1 Risk of death and failure in fluoroquinolone (FQ)-
resistant versus FQ-susceptible multidrug-
resistant tuberculosis cases from Estonia,
Germany, Italy and the Russian Federation
among cases achieving a final outcome
(treatment success, death and failure)
FQ-resistant FQ-susceptible Univariate analysis
RR (95% CI) p-value
Subjects n 87 338
Treatment
success
30 (34) 157 (46)
Death# 17 (20) 40 (12) 1.86 (1.11–3.11) 0.020
Failure# 13 (15) 31 (9) 1.84 (1.05–3.23) 0.038
Data are presented as n (%), unless otherwise indicated. Cases not achieving a
final outcome (default, still on treatment) were excluded from the analysis. RR:
relative risk; CI: confidence interval. #: comparison of treatment success and
treatment failure/death between FQ-resistant and FQ-susceptible multidrug-
resistant tuberculosis cases.
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Concomitant use of b-blockers and b2-agonists
To the Editors:
Historically, the use of b-adrenergic blockers in patients with
airways disease has been discouraged. However, recent meta-
analyses suggest that cardioselective b-blockers are safe in
people with mild-to-moderate airways disease [1, 2]. We have
identified patients with chest disease on b-agonist bronchodila-
tors, who were simultaneously taking b-blocker drugs. We have
also looked at the reasons for co-prescription of these ‘‘com-
peting’’ drugs and whether cardioselective b-blockers were
being used.
Over 2 yrs (2005–2006) in a district general hospital, C.D. Shee
prospectively recorded the names of patients he saw who were
concomitantly taking b-blockers and b2-agonists. Patients were
encountered in outpatient clinics, as hospital in-patients and as
referrals (consults). The data were analysed retrospectively. A
total of 34 patients were identified and hospital notes were
found for 27 (18 males, mean (range) age 69 (54–88) yrs). It
seemed that the co-prescription of these drugs was often
inadvertent. In no instance did the hospital notes nor the
general practitioners’ letter specifically mention why two
competing drug classes were being used simultaneously. It
was not always clear whether it was a general practitioner
(family doctor) or a hospital doctor who had originally
instigated specific drugs.
Of the patients using b-agonists, 19 had diagnoses of chronic
obstructive airways disease and eight had asthma. A total of 21
(78%) subjects were taking salbutamol via a metered-dose
inhaler, four (15%) were taking nebulised salbutamol and two
(7%) were taking a long-acting bronchodilator. Cardioselective
b-blockers were being taken by 18 (67%) subjects (atenolol n514,
bisoprolol n53, metoprolol n51) and nine (33%) subjects were
taking nonselective b-blockers (carvedilol n53, sotalol n52,
propanolol n52, oxprenolol n51, carvedilol with sotalol n51).
Eight (30%) subjects were taking b-blockers primarily for heart
failure, eight (30%) for isolated hypertension and five (19%) for
hypertension with ischaemic heart disease. Other indications
were for angina (two subjects), atrial fibrillation (one subject),
migraine (one subject), hyperthyroidism (one subject) and
unclear (one subject).
In a separate study, on a 1-day in-patient survey (November
21, 2006), drug charts were analysed for 198 patients identified
on eight medical wards. Of these, 32 (16%) subjects were taking
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